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Background: The role of chemotherapy given concurrently with thoracic three-dimensional radiotherapy for stage
IV non-small cell lung cancer (NSCLC) is not well defined. We performed this study to investigate overall survival
and toxicity in patients with stage IV NSCLC treated with this modality.
Methods: From 2003 to 2010, 201 patients were enrolled in this study. All patients received chemotherapy with
concurrent thoracic three-dimensional radiotherapy. The study endpoints were the assessment of overall survival
(OS) and acute toxicity.
Results: For all patients, the median survival time (MST) was 10.0 months, and the 1-, 2- and 3-year OS rates were
40.2%, 16.4%, and 9.6%, respectively. The MST was 14.0 months for patients who received a total radiation dose
≥63 Gy to the primary tumor, whereas it was 8.0 months for patients who received a total dose <63 Gy (P = 0.000).
On multivariate analysis, a total dose ≥63 Gy, a single site of metastatic disease, and undergoing ≥4 cycles of
chemotherapy were independent prognostic factors for better OS (P = 0.007, P = 0.014, and P = 0.038, respectively);
radiotherapy involving metastatic sites was a marginally significant prognostic factor (P = 0.063). When the whole
group was subdivided into patients with metastasis at a single site and multiple sites, a higher radiation dose to the
primary tumor remained a significant prognostic factor for improved OS. For patients who received ≥4 cycles of
chemotherapy, high radiation dose remained of benefit for OS (P = 0.001). Moreover, for the subgroup that received
<4 chemotherapy cycles, the radiation dose was of marginal statistical significance regarding OS (P = 0.063).
Treatment-related toxicity was found to be acceptable.
Conclusions: Radiation dose to primary tumor, the number of metastatic sites, and the number of chemotherapy
cycles were independent prognostic factors for OS in stage IV NSCLC patients treated with concurrent
chemoradiotherapy. In addition to systemic chemotherapy, aggressive thoracic radiotherapy was shown to play an
important role in improving OS.
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For non-small cell lung cancer (NSCLC) patients with stage
IV disease and a good performance status, platinum-based
combination therapy improves survival and quality of life
[1]. However, survival time has not been obviously in-
creased using chemotherapy over the past 10–15 years [2].
Systemic chemotherapy is the standard treatment modality
for stage IV NSCLC, and thoracic radiotherapy is most typ-
ically used for palliation [1,3-5]. Thoracic radiotherapy is an
effective way to relieve symptoms (hemoptysis, cough,
chest pain, dyspnea, and others) that are caused by the
locoregional growth of tumor, and can improve the sur-
vival of patients with better performance status using
higher radiation doses [4,5]. Wagner et al. [6] pointed out
that one of the limitations of published studies concerning
patients receiving radiation therapy for stage IV NSCLC is
the lack of data on the use of chemotherapy in these
patients.
There is increasing evidence that selected patients with
stage IV disease could benefit from aggressive thoracic
radiotherapy beyond palliative irradiation [7-9]. However,
most of the published data include only small patient
numbers, and two-dimensional radiation therapy (2D-RT)
has commonly been used. Moreover, the role of chemo-
therapy given concurrently with thoracic radiotherapy for
stage IV NSCLC patients is not well defined; concurrent
chemoradiotherapy is not recommended as routine treat-
ment modality, with the exception of clinical trials [5].
Given these concerns, we sought to determine if con-
current chemotherapy and thoracic three-dimensional
conformal radiotherapy (3D-CRT) or intensity-modulated
radiotherapy (IMRT) are safe, efficient and feasible treat-
ment modalities for patients with stage IV NSCLC. Thus,
we performed this prospective study to investigate patient
survival and toxicity regarding this treatment modality in
our single institution (Additional file 1).
Methods
Patient selection and pretreatment evaluation
Since January 2003, patients with stage IV NSCLC that ful-
filled all of the following criteria have been treated using a
prospective institutional protocol at the Affiliated Hospital
of GuiYang Medical College, and Guizhou Cancer Hospital
China. The inclusion criteria were as follows: 1) histologi-
cally or cytology confirmed NSCLC; 2) newly diagnosed
stage IV disease according to the staging system of the
2002 American Joint Committee on Cancer (AJCC); 3) an
age of 18–80 years; 4) a Karnofsky Performance Status
score ≥70%; 5) adequate bone marrow, liver and renal
function; neutrophils ≥ 1.5 × 109/L, platelets 80 × 109/L,
hemoglobin ≥80 g/L, AST and ALT ≤2× the upper limit of
the institutional normal range, total bilirubin ≤1.25× the
upper limit of the institutional normal range, and creatin-
ine concentration ≤120 μmol/L; 6) no contraindication forradiotherapy and chemotherapy; 7) limited metastatic dis-
ease (≤5 sites); 8) patients were expected to receive thor-
acic radiotherapy at a dose of ≥40 Gy in 20 fractions. The
exclusion criteria were as follows: 1) a history involving
thoracic surgery, radiotherapy or chemotherapy; 2) preg-
nancy or lactation; 3) previous malignancy or other con-
comitant malignant disease. This prospective study was
reviewed by the ethical review boards in China (Ethics
Committee of the Affiliated Hospital of Guiyang Medical
University, GuiYang, China), and the informed consent for
treatment was obtained from all patients.
Pretreatment evaluation included a complete physical
examination and hematologic and biochemistry profiles.
Examinations using fiberoptic bronchoscopy and contrast-
enhanced computed tomography (CT) of chest were
performed to accurately evaluate the extent of the primary
tumor and regional lymph nodes. Bone scintigraphy,
contrast-enhanced CT of the abdominal region, and
magnetic resonance imaging of the head were routinely
used to detect distant metastases. Additional investiga-
tions were performed if indicated.
Thoracic radiotherapy protocol
All patients were immobilized in the supine position
using a T bar, wing board, and Vac-lock cradle. Images
with contrast were obtained from the CT simulator for
treatment planning purposes. All patients were scanned
using serial 5-mm slices from the hyoid bone through to
the third lumbar vertebra. All patient 3D-CRT or IMRT
treatment plans were performed using the ADAC pinna-
cle planning system (version 7.4f ) and dose distribution
was computed with a tissue heterogeneity correction.
The gross tumor volume (GTV) included thoracic pri-
mary tumors and the visible mediastinal lymph nodes on
the treatment planning CT scan; the planning target vol-
ume (PTV) was defined as the GTV plus a 1.5-cm margin
for setup uncertainty and respiratory motion. Radiation
was delivered using a linear accelerator that generated 6
MV photons. The V20 (percentage of the total lung vol-
ume receiving ≥20 Gy), the maximal point dose for the
spinal cord and the mean esophagus dose were required
to be ≤32%, ≤50 Gy and ≤35 Gy, respectively, for individ-
ual treatment plans.
Patients received late-course accelerated hyperfractionated
radiotherapy (LCAHRT) to the thoracic primary site using
3D-CRT or IMRT techniques. The first course of radio-
therapy was given in 2 Gy fractions, 5 days a week to a
total dose of 40 Gy; LCAHRT was delivered in two frac-
tions of 1.5 Gy each with an interval of 6–8 h per day. It
was decided to deliver a prescription dose of 60–70 Gy to
patients; if individual tolerability was not acceptable, lower
doses of ≥40 Gy would be given. The PTV should be
covered by at least the 90% isodose surface. At acceptable
radiation doses to the normal tissue, radiation dose to the
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acic radiation treatment was implemented concurrently
with chemotherapy.
Chemotherapy protocol
Platinum-based doublets chemotherapy was used for all
patients; the selection of regimens was in accordance
with prior studies [10,11]. Concurrent thoracic radiation
was given within 1 week following the start of chemo-
therapy. The commonly used regimens and usage were
as follows: 140 mg/m2 of paclitaxel (P) or 75 mg/m2
of docetaxel (D) on day 1, followed by 80 mg of
cisplatinum (C) per square meter of body-surface area
(mg/m2) or carboplatin (Cb) at a dose calculated to pro-
duce an area under the concentration-time curve of
6.0 mg/ml/min were administrated on day 2; and
vinorelbine (V) was administered at a dose of 25 mg/m2
on days 1 and 8 during thoracic radiotherapy every
21 days. After completion of thoracic radiotherapy, pa-
tients demonstrating a response or stable disease con-
tinued chemotherapy up to 4–6 cycles, whereas patients
who experienced progressive disease or unacceptable
toxicity were transferred to second-line therapy. Plat-
inum and taxane-based chemotherapy were the main
regimens used in the current study; the number of pa-
tients who received P and C or P and Cb, D and C or D
and Cb, and V and C arms was 83, 103, and 15, respect-
ively. The total number of cycles delivered for all pa-
tients was 617 (mean number per patient, 3.0).
Evaluation of treatment-related toxicity and response
Treatment-related acute toxicity was scored according to
the National Cancer Institute’s Common Terminology Cri-
teria for Adverse Events (CTC) version 3.0. During the
course of treatment, a routine blood test was performed at
least once per week; and routine blood, liver function, and
renal function tests and electrocardiograms were examined
prior to chemotherapy. If necessary, chest X-ray or CT
examination and barium meal radiography were used to
evaluate radiation pneumonitis and esophagitis. Treatment
response was assessed by extramural reviewers using the
Response Evaluation Criteria in Solid Tumors (RECIST).
Follow-up and statistical analysis
After the completion of treatment, the patients were
subsequently followed up monthly for the first 3 months,
every 3 months for 2 years, and then every 6 months.
Intent-to-treat analyses were performed on data from all
patients who entered the study. The endpoints of this
study included overall survival (OS) and acute toxicity.
The overall survival time was measured from the first
day of concurrent chemoradiotherapy to the date of
death or the last follow-up. The Statistical Package for
Social Sciences, version 13.0 (SPSS, Chicago, IL, USA)was used for statistical analysis. The Kaplan-Meier
method was used to calculate the OS. The log-rank test
was used to compare the survival curves. Multivariate
Cox regression analysis was used to test independent
significant prognostic factors for OS. All statistical tests




From January 2003 to July 2010, a total of 201 cases
were enrolled in this study. The clinical characteristics
are listed in Table 1. The most common site of meta-
static disease at diagnosis was the bone (52% of pa-
tients); 69 (34%) patients had lung metastasis and 55
(27%) had metastasis in brain. One hundred and twenty-
one (60%) patients had metastasis in only one site, 53 in
the bone, 25 in the lung, 22 in the brain, 5 in the liver, 5
in the adrenal glands, and 11 in other locations. The me-
dian follow-up period was 9.5 (range, 1–55) months. A
median radiation dose of 63 (range, 30–72) Gy was de-
livered to the primary tumor. For the whole group, 18
patients received <40 Gy to the primary tumor; among
these 18 patients, 10 gave up treatment following radio-
therapy on personal grounds, and eight refused following
radiotherapy because of emerging new metastasis. In
total, 98 patients received radiotherapy concurrently or
sequentially with chemotherapy for metastatic lesions in
3–10 Gy daily fractions to a total dose of 20–60 Gy.
For all patients, the median survival time (MST) was
10.0 months (95% CI, 8.50–11.50), and the 1-, 2-, and 3-
year OS rates were 40.2%, 16.4%, and 9.6%, respectively.
The MST, and 1-, 2-, and 3-year OS rates were 14.0 (95%
CI, 11.86–16.14) months, and 58.7%, 22.0%, and 16.3%, re-
spectively for patients who received a thoracic radiation
dose ≥63 Gy; whereas the MST was 8.0 (95% CI, 7.01–8.99)
months, and 24.2%, 11.4%, and 3.8%, respectively for pa-
tients who received a dose <63 Gy. The difference between
the groups that received ≥63 Gy and <63 Gy was statisti-
cally significant (P = 0.00; Figure 1). Patients who re-
ceived radiotherapy for metastasis had a longer MST
than those who did not receive radiotherapy for me-
tastasis (13.0 months vs. 8.0 months; P = 0.003).
Contrast-enhanced CT of the chest was performed to
evaluate the treatment response of the primary tumor.
Chest X-ray was not used to evaluate the treatment re-
sponse and local control of the primary tumor. In total,
90% (181/201) of patients received CT examination at
1 month after completion of thoracic irradiation, and 74.6%
(150/201) patients received further CT examination of the
chest after 1 month. At 1 month after thoracic radiother-
apy, 69% (125/181) of patients were confirmed to have
responded to the treatment, including 6.6% (12/181) of
patients with a complete response (CR), 62.4% (113/181)
Table 1 Clinical characteristics (201 patients)

















Prescribed dose 63 (22–72)
<63Gy 108 53.7
≥63Gy 93 46.3












Response of primary tumor
Complete response 12 6.0





Patients with 1 metastatic site Yes 76 62.8
No 45 37.2
Patients with ≥2 metastatic sites Yes 22 27.5
No 58 72.5
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disease (SD), and 8.8% (16/181) with progressive disease
(PD). Among these 181 patients, there was a significant as-
sociation between the treatment response of the primary
tumor and survival; patients with a response (CR + PR) had
a longer MST than those without a response (SD + PD)
(13.0 months vs. 7.0 months; P = 0.001). Patients receiving
≥63 Gy to the primary tumor had higher rates of treatment
response as compared with those receiving <63 Gy (84.9%
vs. 52.3%; P = 0.000). With regard to multivariate analysis,
patients with a treatment response (HR, 0.88; P = 0.005)
had an improved OS.
OS was significantly prolonged in patients who re-
ceived ≥4 cycles of chemotherapy relative to those who
received <4 cycles; the MSTs for these two groups were
14.0 months (95% CI, 11.37–16.63) and 8.0 months
(95% CI, 6.67–9.33; P = 0.001; Figure 2), respectively.
For the subset of patients who received ≥4 cycles, the sur-
vival time differed significantly between patients that had
received a radiation dose ≥63 Gy and those that had re-
ceived a radiation dose <63 Gy (P = 0.001; Figure 3); the
MSTs for these two groups were 16 months (95% CI,
14.00–18.00) and 8 months (95% CI, 5.95–10.05), respect-
ively. For patients who received <4 cycles, this difference
between patients that had received a radiation dose ≥63 Gy
and those that had received a radiation dose <63 Gy was of
marginal statistical significance (P = 0.063).
The MST for patients with a single metastatic site was
12.0 months (95% CI, 9 · 50–14 · 50) whereas for patients
with ≥ 2 metastatic sites it was 8.0 months (95% CI,
6.85–9.34; P = 0.002; Figure 4). For the subset with single
site metastasis, the MST for patients that had received
a radiation dose ≥63 Gy to the primary tumor was
17.0 months (95% CI, 13.0–21.0) whereas it was
9.0 months (95% CI, 7.0–11.0) for patients that had re-
ceived a dose <63 Gy (P = 0.001). The location of metas-
tasis (brain, bone, or other locations) was not related to
OS (P = 0.213). When the whole group was subdivided
into patients with metastasis at a single site and multiple
sites, multivariate analysis showed that patients receiving
a radiation dose ≥63 Gy to the primary tumor had a
significantly better OS (Table 2).
Univariate analysis showed that pathological type, gen-
der, age, T-stage, and N-stage were not associated with
OS. For the whole group, multivariate analysis indicated
that a radiation dose ≥63 Gy to the primary tumor, a sin-
gle site of metastatic disease, and a number of chemo-
therapy cycles ≥4 were independent prognostic factors
for better OS; radiation to metastatic sites was margin-
ally significant in this regard (Table 2).
Treatment toxicity
For the whole group, the incidence of acute Grade 2 to
Grade 3 gastrointestinal toxicity was 45.2%, and no
Figure 1 Comparison of dose–response curves for overall survival at different radiation doses.
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Hematologic toxicity was the most common and severe
complication. The incidence of acute Grade 3 to 4 leu-
kocytes, thrombocytopenia, and anemia was 34.8%,
17.9%, and 15.4%, respectively. The most frequently
observed acute pneumonitis or esophagitis was mainly
Grade 0 or Grade 1. The incidence of acute Grade 2–3
pneumonitis and esophagitis was 9.5% and 13.5%, re-
spectively. Table 3 shows the toxicity data for the
whole group.Figure 2 Comparison of overall survival curves with regard to differeDiscussion
In the present series, we sought to determine whether or
not thoracic 3D-CRT using concurrent third-generation
chemotherapy regimens could improve OS for patients
with stage IV NSCLC. As compared with historical
data concerning patients who had been treated with
third-generation chemotherapy regimens or newer agents
(e.g. pemetrexed) [10-12], the survival times of patients in
the current study were not decreased. We found that the
system of chemotherapy involved in the thoracic 3D-CRTnt chemotherapy cycles.
Figure 3 Comparison of dose–response curves for overall survival at different radiation doses for patients treated with ≥4
chemotherapy cycles.
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ity for patients with stage IV NSCLC. Our results also sug-
gested that radiation doses ≥63 Gy to the primary tumor, a
single site of metastatic disease, radiotherapy for meta-
static sites and >4 cycles of chemotherapy were independ-
ent prognostic factors for better OS in stage IV NSCLC
patients treated with concurrent chemoradiotherapy.
Fairchild et al. [4] reported the results of a systematic
review of 13 randomized controlled trials involving pallia-
tive thoracic radiation, and found that an improvement
in survival and symptoms was seen with higher-doseFigure 4 Comparison of overall survival curves between single site mradiation schedules as compared with lower dose radi-
ation schedules. Lopez et al. [7] suggested that the deliv-
ery of at least 63 Gy to the primary tumor was associated
with improved OS in patients with oligometastatic
NSCLC at diagnosis. The results of our analysis of thor-
acic radiotherapy concur with the findings of Fairchild
et al. [4] and Lopez et al. [7], namely that higher-dose ra-
diation treatment had a greater likelihood of improving
survival.
There was a limitation to the current study, in that
consistent imaging data were not gained in a proportionetastases and multi-sites metastases.
Table 2 Multivariate analysis of parameters for the prediction of overall survival
Variable All patients Patients with single sites of metastasis Patients with ≥2 sites of metastasis
HR P value HR P value HR P value
Sex(female vs. male) 0.742 0.117 0.605 0.079 0.786 0.201
Age(<60y vs. ≥60y) 0.841 0.288 0.915 0.740 0.856 0.340
Pathological type (squamous vs. non-squamous ) 0.991 0.957 0.919 0.767 0.973 0.872
T stage(T3-4 vs. T1-2) 1.109 0.537 1.178 0.667 1.188 0.296
N stage(N2-3 vs. N0-1) 1.286 0.232 1.213 0.597 1.305 0.208
Thoracic radiation dose 0.615 0.007 0.576 0.045 0.619 0.008
(≥63Gy vs. <63Gy)
Radiotherapy to metastases(yes vs. no) 0.729 0.063 0.340 0.001 0.674 0.017
Chemotherapy cycles 0.693 0.038 0.625 0.079 0.691 0.039
(≥4 cycles vs. < 4 cycles)
Metastasis status 1.513 0.014 - - - -
(multi- vs. single)
Su et al. BMC Cancer 2013, 13:474 Page 7 of 9
http://www.biomedcentral.com/1471-2407/13/474of patients for the evaluation of the relationship between
OS and local-regional control (LCR). Several publica-
tions have confirmed that higher radiation doses are as-
sociated with improved local tumor control and OS in
patients with NSCLC [7,13]. Although we did not obtain
data regarding LCR in our study, the results indicate that
higher radiation dose to the primary tumor and treat-
ment response were prognostic factors for better OS.
From the results of the present study, we speculate that
aggressive local therapy to primary tumor can improve
OS. A retrospective analysis by Lopez et al. [7] also indi-
cated that aggressive local therapy to the primary tumor
can improve OS for patients with oligometastatic NSCLC.
Consistent with the conclusion of a study by Scagliotti
et al. [10], we found that the number of distant meta-
static sites was associated with OS. However, it is worth-
while noting that higher radiation dose delivery to the
primary tumor and radiotherapy for metastatic sites
were independent prognostic factors for better OS, when
patients with metastasis in single site and those with
multiple sites were analyzed separately. Our results indi-
cated that aggressive radiation treatment at the primary
tumor and metastatic site translated to improved OS,
whether or not patients had metastasis at a single site or
multiple sites. Several recent publications have alsoTable 3 Incidence of acute toxicity (201 patients)
Adverse effects Grade 0 to 1 Grade 2 Grade 3 Grade 4
Gastrointestinal 110 (54.7) 64(31.8) 27(13.4) 0 (0.0)
Leukocytes 67 (33.3) 64(31.8) 48(23.9) 22(10.9)
Platelet 145 (72.1) 20(9.9) 26(12.9) 10(5.0)
Hemoglobin 120(59.7) 50(24.9) 21(10.4) 10(5.0)
Pneumonitis 182(90.5) 11(5.5) 8(4.0) 0(0.0)
Esophagitis 174(86.6) 24(12.0) 3(1.5) 0(0.0)shown that patients with limited metastases may benefit
from radiotherapy for the primary tumor and distant
metastasis [7-9].
A consensus on the use of chemotherapy administered
concurrently with radiotherapy for stage IV NSCLC has
not been reached. The findings from a retrospective study
by Lopez et a1. [7] revealed that higher radiation doses to
the primary tumor are associated with improved OS in pa-
tients with oligometastatic NSCLC; most of the patients
(67%) received platinum and taxane-based concurrent
chemotherapy. These authors found [7] that patients that
received concurrent chemoradiotherapy had a trend in-
volving improved OS relative to those that did not
undergo chemoradiotherapy (P = 0.055). We searched the
PubMed data base thoroughly and found only one ran-
domized phase III study that had directly assessed
whether or not patients with advanced NSCLC would
benefit from chemotherapy administered concurrently
with thoracic palliative radiotherapy [14]. The random-
ized phase III study by Ball et al. [14] revealed that the
addition of chemotherapy to radiotherapy resulted in no
improvement in survival; the MST was 6.8 months in
patients treated with chemoradiotherapy, whereas it
was 6.0 months in patients who were treated with radi-
ation alone. It is worthwhile to notinge that fluorouracil,
which is an outmoded agent that is rarely used in sys-
temic therapy for NSCLC, was administered concur-
rently with radiotherapy as a palliative treatment for
intrathoracic disease using 2D-radiotherapy in a study
by Ball et al. [14]. Our results showed that a higher radi-
ation dose to the primary tumor concurrent with
chemotherapy for stage IV NSCLC resulted in a consid-
erable improvement in survival. As compared with the
study by Ball et al. [14], patient survival in our study
was improved. This may have been due in part to the
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and V were used in our study; these agents have been
identified as improving survival [15]. Secondly, the use
of modern radiotherapy technologies (IMRT or 3D-
CRT) with higher doses (median dose, 63 Gy) have been
used to improve the local control of thoracic tumors;
this has contributed to a reduction in the death rate
caused by locoregional growth of tumor and decreased
the sources of metastasis.
Although we used different chemotherapy regimens for
patients, they had similar response rates and survival times
in the treatment of advanced NSCLC [10,16]. In the
current study, the effect of the number of chemotherapy
cycles on OS was also found to be statistically significant
using multivariate analysis. The recommended number
of chemotherapy cycles for stage IV NSCLC was 4–6
according to the ASCO guidelines [3]. We found that
when patients were grouped according to the number of
chemotherapy cycles, those that received ≥4 cycles of
chemotherapy exhibited a prolongation of survival time.
Moreover, for the subgroup that received ≥4 cycles of
chemotherapy, we observed that higher radiation doses
(≥63 Gy) to the primary tumor could improve OS. For the
subgroup that received <4 cycles of chemotherapy, there
was a trend for improved OS at higher radiation doses. In
patients with stage IV NSCLC, thoracic irradiation is most
typically delivered for palliation [3-5]. Our findings indi-
cated that patients can benefit from aggressive radiation
treatment (≥63 Gy) to the primary tumor based on the de-
livery of a sufficient number of cycles (≥4 cycles) of sys-
temic chemotherapy. There was no randomization in the
current trial. Further evidence is needed to determine
whether or not thoracic radiotherapy with concurrent
chemotherapy is superior to chemotherapy alone, and if
NSCLC patients with limited metastasis can benefit from
higher radiation doses.
The use of concurrent chemoradiotherapy is not recom-
mended for advanced NSCLC. This is because of one
important factor, namely that toxicity is increased by
concurrent chemoradiotherapy relative to radiation alone.
Concurrent chemoradiotherapy has become a standard of
treatment for patients with unresectable locally advanced
NSCLC. The incidence of toxicity in the current study (in-
cluding hematologic and non-hematologic toxicity) was
not increased, as compared with studies of concurrent
treatment with radiotherapy and chemotherapy in locally
advanced NSCLC [17]. As far as toxicity is concerned,
concurrent chemoradiotherapy could be acceptable for
stage IV NSCLC.
Conclusions
Patients with stage IV NSCLC with good performance
status who were treated with higher radiation doses
(≥63 Gy) to the primary tumor concurrently withsystemic chemotherapy had improved survival outcomes
with acceptable toxicity; this was especially true for pa-
tients with single metastatic sites. Patients can benefit
from higher radiation doses to the primary tumor, whether
they have metastasis at a single site or multiple sites. We
found that among patients who had undergone ≥4 cycles
of chemotherapy, those that had received higher radiation
doses (≥63 Gy) to the primary tumor benefited. For the
subgroup who received <4 cycles of chemotherapy, higher
radiation doses had a trend that involved improved OS.
Our findings suggest that patients benefit from higher ra-
diation doses (≥63 Gy) to the primary tumor based on
their having received a sufficient number of cycles (≥4) of
systemic chemotherapy. In addition to systemic chemo-
therapy, clinicians should consider aggressive thoracic
radiotherapy beyond palliative intent.
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